Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by TD Asset Management Inc.

TD Asset Management Inc. decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 463,961 shares of the company’s stock after selling 39,113 shares during the period. TD Asset Management Inc.’s holdings in Medpace were worth $154,142,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Proficio Capital Partners LLC grew its stake in Medpace by 34,497.4% during the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock worth $80,575,000 after purchasing an additional 241,827 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Medpace in the 4th quarter valued at about $78,144,000. Iron Triangle Partners LP acquired a new position in shares of Medpace during the third quarter worth about $64,371,000. GW&K Investment Management LLC increased its stake in shares of Medpace by 93.9% during the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after buying an additional 133,379 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after buying an additional 109,886 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on MEDP shares. Robert W. Baird boosted their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research report on Monday. Finally, Leerink Partners started coverage on Medpace in a report on Monday. They issued a “market perform” rating and a $330.00 target price on the stock. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $376.30.

Medpace Stock Performance

Shares of MEDP stock opened at $324.51 on Wednesday. The stock’s 50-day moving average is $337.16 and its two-hundred day moving average is $339.57. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The firm has a market cap of $9.89 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.